Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio

• Market Driver: The approval of novel drugs is driving the growth of the market. For the treatment of neurologic indications such as schizophrenia, bipolar disorder, depression, ADHD, and OCD, Several drugs have been approved. For instance, in April 2021, the US FDA approved Qelbree of Supernus Pharmaceuticals for treating ADHD in children aged between 6 and 17 years. Moreover, several other drugs for the treatment of indications such as ADHD, schizophrenia, and bipolar disorder have received marketing approval from the US FDA and the EMA. The rising number of drug approvals is expected to address the unmet need, which will contribute to the growth of the global neurologic disorders therapeutics market during the forecast period.
• Market Challenge: The advent of neurostimulation devices is challenging the growth of the market. Non-invasive neuromodulation devices are expected to gain importance in the coming years. For instance, NeuroPace Inc. has developed the RNS System, which has been approved by the US FDA as an adjunctive treatment for adults with medically refractory partial seizures. Therefore, ongoing research activities and the recent approval of neuromodulation devices, along with their use for the treatment of various neurologic disorders, will challenge the growth of the global neurologic disorders therapeutics market during the forecast period.

Be up-to-date with the latest drivers, trends, and challenges in the market. View our Sample Report

North America will be the leading region with 37% of the market's growth during the forecast period. The US and Canada are the key countries for the neurologic disorders therapeutics market in North America. The growth of the market in the region will be driven by factors such as the strong dominance of generics. Moreover, market growth in this region will be faster than the growth of the market in other regions.

The CNS application segment will contribute the highest market share growth during the forecast period. Central nervous system (CNS) disorders affect the nervous system and can be classified into functional disorders and degeneration disorders. Recent drug approvals are expected to significantly benefit this segment, which will drive the neurologic disorders therapeutics market growth during the forecast period.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Sample Report

• AbbVie Inc.
• Acadia Pharmaceuticals Inc.
• Acorda Therapeutics Inc.
• Bayer AG
• Biogen Inc.
• Eisai Co. Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• H Lundbeck AS
• Johnson and Johnson
• Merck KGaA
• Mylan NV
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB SA
• USWM LLC

Want your report customized? Speak to an analyst and personalize your report according to your needs.

Neurodegenerative Diseases Therapeutics Market by Indication and Geography - Forecast and Analysis 2022-2026: The neurodegenerative diseases therapeutics market size is predicted to surge by USD 19.74 billion from 2021 to 2026.

Neuromuscular Disease Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025: The neuromuscular disease therapeutics market share is expected to increase by USD 4.46 billion from 2020 to 2025.

Browse Health Care Market Research Reports

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ billion)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ billion)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Application

• 5.1 Market segments
• Exhibit 24: Chart on Application - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Application - Market share 2021-2026 (%)

• 5.2 Comparison by Application
• Exhibit 26: Chart on Comparison by Application
• Exhibit 27: Data Table on Comparison by Application

• 5.3 CNS - Market size and forecast 2021-2026
• Exhibit 28: Chart on CNS - Market size and forecast 2021-2026 ($ billion)
• Exhibit 29: Data Table on CNS - Market size and forecast 2021-2026 ($ billion)
• Exhibit 30: Chart on CNS - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on CNS - Year-over-year growth 2021-2026 (%)

• 5.4 PNS - Market size and forecast 2021-2026
• Exhibit 32: Chart on PNS - Market size and forecast 2021-2026 ($ billion)
• Exhibit 33: Data Table on PNS - Market size and forecast 2021-2026 ($ billion)
• Exhibit 34: Chart on PNS - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on PNS - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Application
• Exhibit 36: Market opportunity by Application ($ billion)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ billion)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ billion)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ billion)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ billion)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ billion)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ billion)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ billion)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ billion)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ billion)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 UK - Market size and forecast 2021-2026
• Exhibit 62: Chart on UK - Market size and forecast 2021-2026 ($ billion)
• Exhibit 63: Data Table on UK - Market size and forecast 2021-2026 ($ billion)
• Exhibit 64: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ billion)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ billion)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ billion)
• Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ billion)
• Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 India - Market size and forecast 2021-2026
• Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ billion)
• Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ billion)
• Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ billion)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 AbbVie Inc.
• Exhibit 85: AbbVie Inc. - Overview
• Exhibit 86: AbbVie Inc. - Product / Service
• Exhibit 87: AbbVie Inc. - Key offerings

• 10.4 Biogen Inc.
• Exhibit 88: Biogen Inc. - Overview
• Exhibit 89: Biogen Inc. - Product / Service
• Exhibit 90: Biogen Inc. - Key offerings

• 10.5 F. Hoffmann La Roche Ltd.
• Exhibit 91: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 92: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 93: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 94: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 95: F. Hoffmann La Roche Ltd. - Segment focus

• 10.6 H Lundbeck AS
• Exhibit 96: H Lundbeck AS - Overview
• Exhibit 97: H Lundbeck AS - Product / Service
• Exhibit 98: H Lundbeck AS - Key offerings

• 10.7 Johnson and Johnson
• Exhibit 99: Johnson and Johnson - Overview
• Exhibit 100: Johnson and Johnson - Business segments
• Exhibit 101: Johnson and Johnson - Key news
• Exhibit 102: Johnson and Johnson - Key offerings
• Exhibit 103: Johnson and Johnson - Segment focus

• 10.8 Novartis AG
• Exhibit 104: Novartis AG - Overview
• Exhibit 105: Novartis AG - Business segments
• Exhibit 106: Novartis AG - Key offerings
• Exhibit 107: Novartis AG - Segment focus

• 10.9 Pfizer Inc.
• Exhibit 108: Pfizer Inc. - Overview
• Exhibit 109: Pfizer Inc. - Product / Service
• Exhibit 110: Pfizer Inc. - Key news
• Exhibit 111: Pfizer Inc. - Key offerings

• 10.10 Sanofi
• Exhibit 112: Sanofi - Overview
• Exhibit 113: Sanofi - Business segments
• Exhibit 114: Sanofi - Key news
• Exhibit 115: Sanofi - Key offerings
• Exhibit 116: Sanofi - Segment focus

• 10.11 Takeda Pharmaceutical Co. Ltd.
• Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 118: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 119: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 120: Takeda Pharmaceutical Co. Ltd. - Key offerings

• 10.12 Teva Pharmaceutical Industries Ltd.
• Exhibit 121: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 122: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 123: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 125: Teva Pharmaceutical Industries Ltd. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 126: Inclusions checklist
• Exhibit 127: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 128: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 129: Research methodology
• Exhibit 130: Validation techniques employed for market sizing
• Exhibit 131: Information sources

• 11.5 List of abbreviations
• Exhibit 132: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

SOURCE Technavio